Kalehua Capital Management LLC

Est. AUM

$118.6M

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	X4 Pharmaceuticals Inc	COM NEW	$15.4M	3722840	12.96%	SOLE
2	Alpha Architect 1-3 Month Box ETF	ALPHA ARCH 1-3	$13.8M	118422	11.61%	SOLE
3	Surrozen Inc	COM NEW	$11.2M	385178	9.46%	SOLE
4	Relay Therapeutics Inc	COM	$9.0M	901457	7.56%	SOLE
5	Sionna Therapeutics Inc	COM	$7.9M	197072	6.66%	SOLE
6	Veradermics Inc	COMMON STOCK	$6.5M	102879	5.48%	SOLE
7	Oruka Therapeutics Inc	COM	$5.8M	118524	4.90%	SOLE
8	Pharvaris NV	COM	$5.6M	198772	4.73%	SOLE
9	ACLARIS THERAPEUTICS INC	COM	$5.0M	1337556	4.23%	SOLE
10	Septerna Inc	COM	$4.7M	194544	3.94%	SOLE
11	Compass Pathways PLC	SPONSORED ADS	$4.5M	819692	3.82%	SOLE
12	Inhibikase Therapeutics Inc	COM NEW	$4.5M	2672608	3.79%	SOLE
13	LeonaBio Inc	COM	$4.0M	393701	3.41%	SOLE
14	Damora Therapeutics Inc	COM NEW	$3.6M	139000	3.04%	SOLE
15	Uniqure NV	SHS	$3.5M	211702	2.92%	SOLE
16	MoonLake Immunotherapeutics	CLASS A ORD	$3.3M	175734	2.76%	SOLE
17	Tyra Biosciences Inc	COM	$2.9M	74465	2.40%	SOLE
18	Gossamer Bio Inc	COM	$2.5M	7471840	2.07%	SOLE
19	Tenaya Therapeutics Inc	COM	$1.4M	2000000	1.17%	SOLE
20	PepGen Inc	COM	$1.3M	729961	1.09%	SOLE
21	Instil Bio Inc	COM NEW	$1.2M	139849	0.97%	SOLE
22	Kalaris Therapeutics Inc	COM	$782K	135585	0.66%	SOLE
23	DiaMedica Therapeutics Inc	COM NEW	$423K	62488	0.36%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.